EctrimsTeam.png

During 11-13 September 2019, the Clinical Trial Team from SNAC , demonstrated its multimodal turnkey central reading solution for Phase 2 Remyelination Clinical Trials, at ECTRIMS 2019 in Stockholm, Sweden.

 

ECTRIMS- European Committee for Treatment and Research in Multiple Sclerosis (MS), started in Europe and has served as world’s largest professional organization for acknowledging and treating multiple sclerosis. ECTRIMS creates and collaborates opportunities for researchers and clinicians worldwide to support clinical research and improve outcomes in MS.

 

Based on its strong neurology and neuroimaging connections with University of Sydney, neuroimaging services provided by SNAC is complemented by its research power, in which it also derives its educational and training strength on MRI-based outcomes interpretation in Morden clinical trialsBased on its strong neurology and neuroimaging connections with University of Sydney, neuroimaging services provided by SNAC is complemented by its research power, in which it also derives its educational and training strength on MRI-based outcomes interpretation in Morden clinical trials.

 

At ECTRIMS 2019, a diverse team of neurologists, clinical trial professionals and neuroimaging specialist from SNAC and their collaborators shared their latest perspectives on MS in clinical trial practice and neuroimaging analysis. Our showcase has highlighted SNAC’s unique approach to providing accurate measurements of remyelination in both acute and chronic MS lesions, which use visual systems as a platform, and facilitate testing of emerging remyelinating therapies.

Ectrims.png

For more information please contact:   

Email: info@snac.com.au

Web: snac.com.au